| Literature DB >> 11136559 |
A Di Biase1, S Salvati, R Varí, C Avellino, F Sforza, M Cappa, R Masella.
Abstract
This paper shows for the first time the higher oxidizability of low-density lipoprotein (LDL) in plasma from adrenoleukodystrophy (ALD) patients compared to that of control subjects. LDL oxidation susceptibility was assessed by conjugate diene formation, hydroperoxide and lipoperoxide formation, and electrophoretic mobility. Simvastatin therapy, an HMG-CoA reductase inhibitor, seems to be a protective pharmacological agent against the higher oxidizability of LDL in plasma from ALD patients. Copyright 2000 Academic Press.Entities:
Mesh:
Substances:
Year: 2000 PMID: 11136559 DOI: 10.1006/mgme.2000.3100
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797